Pliant Therapeutics Statistics
Total Valuation
PLRX has a market cap or net worth of $74.92 million. The enterprise value is -$86.30 million.
Important Dates
The next estimated earnings date is Wednesday, May 6, 2026, after market close.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
PLRX has 61.91 million shares outstanding. The number of shares has increased by 1.37% in one year.
| Current Share Class | 61.91M |
| Shares Outstanding | 61.91M |
| Shares Change (YoY) | +1.37% |
| Shares Change (QoQ) | +0.07% |
| Owned by Insiders (%) | 2.73% |
| Owned by Institutions (%) | 77.13% |
| Float | 60.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.41 |
| P/TBV Ratio | 0.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.00, with a Debt / Equity ratio of 0.16.
| Current Ratio | 12.00 |
| Quick Ratio | 11.72 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -58.65 |
Financial Efficiency
Return on equity (ROE) is -61.55% and return on invested capital (ROIC) is -32.65%.
| Return on Equity (ROE) | -61.55% |
| Return on Assets (ROA) | -30.15% |
| Return on Invested Capital (ROIC) | -32.65% |
| Return on Capital Employed (ROCE) | -71.85% |
| Weighted Average Cost of Capital (WACC) | 9.94% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.05M |
| Employee Count | 49 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -16.78% in the last 52 weeks. The beta is 1.24, so PLRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.24 |
| 52-Week Price Change | -16.78% |
| 50-Day Moving Average | 1.29 |
| 200-Day Moving Average | 1.43 |
| Relative Strength Index (RSI) | 40.36 |
| Average Volume (20 Days) | 556,532 |
Short Selling Information
The latest short interest is 3.64 million, so 5.88% of the outstanding shares have been sold short.
| Short Interest | 3.64M |
| Short Previous Month | 4.03M |
| Short % of Shares Out | 5.88% |
| Short % of Float | 6.04% |
| Short Ratio (days to cover) | 7.75 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -150.07M |
| Pretax Income | -149.34M |
| Net Income | -149.34M |
| EBITDA | -148.38M |
| EBIT | -150.07M |
| Earnings Per Share (EPS) | -$2.43 |
Full Income StatementBalance Sheet
The company has $190.94 million in cash and $29.11 million in debt, giving a net cash position of $161.84 million or $2.61 per share.
| Cash & Cash Equivalents | 190.94M |
| Total Debt | 29.11M |
| Net Cash | 161.84M |
| Net Cash Per Share | $2.61 |
| Equity (Book Value) | 181.21M |
| Book Value Per Share | 2.95 |
| Working Capital | 180.08M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$128.34 million and capital expenditures -$374,000, giving a free cash flow of -$128.71 million.
| Operating Cash Flow | -128.34M |
| Capital Expenditures | -374,000 |
| Depreciation & Amortization | 1.70M |
| Net Borrowing | -32.27M |
| Free Cash Flow | -128.71M |
| FCF Per Share | -$2.08 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |